[1]
|
S. Sultan and N. Hynes, “Cardiovascular Disease: Primary Prevention, Disease Modulation and Regenerative Therapy,” Vascular, Vol. 20, No. 5, 2012, pp. 243-250.
doi:10.1258/vasc.2012.ra0062
|
[2]
|
S. Ebrahim, F. Taylor, K. Ward, A. Beswick, M. Burke and G. Davey, “Smith Multiple Risk Factor Interventions for Primary Prevention of Coronary Heart Disease,” Cochrane Database of Systematic Reviews, Vol. 19, 2011, Article ID: CD001561.
doi:10.1002/14651858.CD001561.pub3
|
[3]
|
F. Taylor, K. Ward, T. H. Moore, M. Burke, G. Davey Smith, J. P. Casas and S. Ebrahim, “Statins for the Primary Prevention of Cardiovascular Disease,” Cochrane Database of Systematic Reviews, Vol. 19, No. 1, 2011, Article ID: CD004816.
doi:10.1002/14651858.CD004816.pub4
|
[4]
|
V. Prasad and A. Vandross, “Cardiovascular Primary Prevention: How High Should We Set the Bar?” Archives of Internal Medicine, Vol. 172, No. 8, 2012, pp. 656-659.
doi:10.1001/archinternmed.2012.812
|
[5]
|
A. A. Bartolucci, M. Tendera and G. Howard, “Meta-Analysis of Multiple Primary Prevention Trials of Cardiovascular Events Using Aspirin,” American Journal of Cardiology, Vol. 107, No. 12, 2011, pp. 1796-1801.
doi:10.1016/j.amjcard.2011.02.325
|
[6]
|
J. Hippisley-Cox and C. Coupland, “Unintended Effects of Statins in Men and Women in England and Wales: Population Based Cohort Study Using the Q Research Database,” British Medical Journal, Vol. 340, 2010, Article ID: c2197.
|
[7]
|
K. El-Salem, B. Ababneh, S. Rudnicki, A. Malkawi, A. Alrefai, Y. Khader, R. Saadeh and M. Saydam, “Prevalence and Risk Factors of Muscle Complications Secondary to Statins,” Muscle Nerve, Vol. 44, No. 6, 2011, pp. 877-881. doi:10.1002/mus.22205
|
[8]
|
Y. Vinogradova, C. Coupland and J. Hippisley-Cox, “Exposure to Statins and Risk of Common Cancers: A Series of Nested Case-Control Studies,” BMC Cancer, Vol. 11, No. 1, 2011, p. 409. doi:10.1186/1471-2407-11-409
|
[9]
|
B. A. Parker, A. L. Augeri, J. A. Capizzi, K. D. Ballard, C. Troyanos, A. L. Baggish, P. A. D’Hemecourt and P. D. Thompson, “Effect of Statins on Creatine Kinase Levels before and after a Marathon Run,” American Journal of Cardiology, Vol. 109, No. 2, 2012, pp. 282-287.
doi:10.1016/j.amjcard.2011.08.045
|
[10]
|
G. Fernandez, E. S. Spatz, C. Jablecki and P. S. Phillips, “Statin Myopathy: A Common Dilemma Not Reflected in Clinical Trials,” Cleveland Clinic Journal of Medicine, Vol. 78, No. 6, 2011, pp. 393-403.
|
[11]
|
A. B. Fernandez, R. H. Karas, A. A. Alsheikh-Ali and P. D. Thompson, “Statins and Interstitial Lung Disease. A Systematic Review of the Literature and of Food and Drug Administration Adverse Event Reports,” Chest, Vol. 134, No. 4, 2008, pp. 824-830. doi:10.1378/chest.08-0943
|
[12]
|
R. Sukhija, S. Prayaga, M. Marashdeh, Z. Bursac, P. Kakar, D. Bansal, R. Sachdeva, S. H. Kesan and J. L. Mehta, “Effect of Statins on Fasting Plasma Glucose in Diabetic and Nondiabetic Patients,” Journal of Investigative Medicine, Vol. 57, No. 3, 2009, pp. 495-499.
|
[13]
|
“Jupiter Subanalysis Rosuvastatin for Cardiovascular Prevention: Too Many Uncertainties,” Prescrire International, Vol. 18, No. 102, 2009, p. 176.
|
[14]
|
S. Ahmed, C. P. Cannon, S. A. Murohy and E. Braunwald, “Acute Coronary Syndromes and Diabetes: Is Intensive Lipid Lowering Beneficial? Results of the PROVE IT-TIMI 22 Trial,” European Heart Journal, Vol. 27, No. 19, 2006, pp. 2323-2329. doi:10.1093/eurheartj/ehl220
|
[15]
|
S. Huptas, H. C. Geiss, C. Otto and K. G. Parhofer, “Effect of Atorvastatin (10 mg/day) on Glucose Metabolism in Patients with the Metabolic Syndrome,” American Journal of Cardiology, Vol. 98, No. 1, 2006, pp. 66-69.
doi:10.1016/j.amjcard.2006.01.055
|
[16]
|
A. L. Culver, I. S. Ockene, R. Balasubramanian, B. C. Olendzki, D. M. Sepavich, J. Wactawski-Wende, J. E. Manson, Y. Qiao, S. Liu, P. A. Merriam, C. Rahilly-Tierny, F. Thomas, J. S. Berger, J. K. Ockene, J. D. Curb and Y. Ma, “Statin Use and Risk of Diabetes Mellitus in Postmenopausal Women in the Women’s Health Initiative,” Archives of Internal Medicine, Vol. 172, No. 2, 2012, pp. 144-152. doi:10.1001/archinternmed.2011.625
|
[17]
|
M. de Lorgeril, P. Salen, J. Abramson, S. Dodin, T. Hamazaki, W. Kostucki, H. Okuyama, B. Pavy and M. Rabeaus, “Cholesterol Lowering, Cardiovascular Diseases, and the Rosuvastatin-JUPITER Controversy: A Critical Reappraisal,” Archives of Internal Medicine, Vol. 170, No. 12, 2010, pp. 1032-1036.
doi:10.1001/archinternmed.2010.184
|
[18]
|
N. Sattar, D. Preiss, H. M. Murray, P. Welsh, B. M. Buckley, A. J. de Craen, S. R. Seshasai, J. J. McMurray, D. J. Freeman, J. W. Jukema, P. W. Macfarlane, C. J. Packard, D. J. Stott, R. G. Westendorp, J. Shepherd, B. R. Davis, S. L. Pressel, R. Marchioli, R. M. Marfisi, A. P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekshus, T. R. Pedersen, T. J. Cook, A. M. Gotto, M. B. Clearfield, J. R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, K. K. Ray and I. Ford, “Statins and Risk of Incident Diabetes: A Collaborative Meta-Analysis of Randomised Statin Trials,” Lancet, Vol. 375, No. 9716, 2010, pp. 735-742.
|
[19]
|
D. Preiss, S. R. Seshasai, P. Welsh, S. A. Murphy, J. E. Ho, D. D. Waters, D. A. DeMicco, P. Barter, C. P. Cannon, M. S. Sabatine, E. Braunwald, J. J. Kastelein, J. A. de Lemos, M. A. Blazing, T. R. Pedersen, M. J. Tikkanen, N. Sattar and K. K. Ray, “Risk of Incident Diabetes with Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-Analysis,” Journal of the American Medical Association, Vol. 305, No. 24, 2011, pp. 2556-2564.
|
[20]
|
K. K. Koh, I. Sakuma and M. J. Quon, “Differential Metabolic Effects of Distinct Statins,” Atherosclerosis, Vol. 2015, No. 1, 2011, pp. 1-8.
|
[21]
|
M. B. Westover, M. T. Bianchi, M. H. Eckman and S. M. Greenberg, “Statin Use Following Intracerebral Hemorrhage: A Decision Analysis,” Archives of Neurology, Vol. 68, No. 5, 2011, pp. 573-579.
|
[22]
|
P. Amarenco, O. Benavente, L. B. Goldstein, A. Callahan 3rd, H. Sillesen, M. G. Hennerici, S. Gilbert, A. E. Rudolph, L. Simunovic, J. A. Zivin and K. M. Welch, “Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SP-ARCL) Trial by Stroke Subtypes,” Stroke, Vol. 40, No. 4, 2009, pp. 1405-1409.
|
[23]
|
K. K. Ray, S. R. Seshasai, S. Erqou, P. Sever, J. W. Jukema, I. Ford and N. Sattar, “Statins and All-Cause Mortality in High-Risk Primary Prevention: A Meta-Analysis of 11 Randomized Controlled Trials Involving 65,229 Participants,” Archives of Internal Medicine, Vol. 170, No. 12, 2010, pp. 1024-1031.
doi:10.1001/archinternmed.2010.182
|
[24]
|
X. Huang, H. Chen, W. C. Miller, R. B. Mailman, J. L. Woodard, P. C. Chen, D. Xiang, R. W. Murrow, Y. Z. Wang and C. Poole, “Lower Low-Density Lipoprotein Cholesterol Levels Are Associated with Parkinson’s Disease,” Movement Disorders, Vol. 22, No. 3, 2007, pp. 377-381
|
[25]
|
C. W. Shults, D. Oakes, K. Kieburtz, M. F. Beal, R. Haas, S. Plumb, J. L. Juncos, J. Nutt, I. Shoulson, J. Carter, K. Kompoliti, J. S. Perlmutter, S. Reich, M. Stern, R. L. Watts, R. Kurlan, E. Molho, M. Harrison, M. Lew and Parkinson Study Group, “Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline,” Archives of Neurology, Vol. 59, No. 10, 2002, pp. 1541-1550.
|
[26]
|
A. Lieberman, K. Lyons, J. Levine and R. Myerburg, “Statins, Cholesterol, Co-Enzyme Q10, and Parkinson’s Disease,” Parkinsonism & Related Disorders, Vol. 11, No. 2, 2005, pp. 81-84.
|
[27]
|
L. Mascetelli, F. Pezzetta and M. R. Goldstein, “Why Statin Therapy May Increase the Risk of Posttransplantation Squamous Cell Carcinoma,” Transplant Immunology, Vol. 23, No. 4, 2010, pp. 224-225.
doi:10.1016/j.trim.2010.06.001
|
[28]
|
J. Kuoppala, A. Lamminpaa and E. Pukkala, “Statins and Cancer: A Systematic Review and Meta-Analysis,” European Journal of Cancer, Vol. 44, No. 15, 2008, pp. 2122-2132. doi:10.1016/j.ejca.2008.06.025
|
[29]
|
H. Rosenberg and D. Allard, “Evidence for Caution: Women and Statin Use Women and Health Protection,” Canadian Government White Paper, June 2007.
|
[30]
|
P. S. Sever, C. L. Chang, A. K. Gupta, A. Whitehouse, N. R. Poulter and ASCOT Investigators, “The Anglo-Scandinavian Cardiac Outcomes Trial: 11-Year Mortality Follow-Up of the Lipid-Lowering Arm in the UK,” European Heart Journal, Vol. 32, No. 20, 2011, pp. 2525-2532.
|
[31]
|
C. M. Machan, P. K. Hrynchak and E. L. Irving, “Age-Related Cataract Is Associated with Type 2 Diabetes and Statin Use,” Optometry & Vision Science, Vol. 89, No. 8, 2012, pp. 1165-1171.
doi:10.1097/OPX.0b013e3182644cd1
|
[32]
|
R. Nakazato, H. Gransar, D. S. Berman, V. Y. Cheng, F. Y. Lin, S. Achenbach, M. Al-Mallah, M. J. Budoff, F. Cademartiri, T. Q. Callister, H. J. Chang, R. C. Cury, K. Chinnaiyan, B. J. W. Chow, A. Delago, M. Hadamitzky, J. Hausleiter, P. Kaufmann, E. Maffei, G. Raff, L. J. Shaw, T. C. Villines, A. Dunning, G. Feuchtner, Y. J. Kim, J. Leipsic and J. K. Mina, “Statins Use and Coronary Artery Plaque Composition: Results from the International Multicenter Confirm Registry,” Atherosclerosis, Vol. 225, No. 1, 2012, pp. 148-153.
|
[33]
|
P. Raggi, M. Davidson, T. Q. Callister, et al., “Aggressive versus Moderate Lipid-Lowering Therapy in Hypercholesterolemic Postmenopausal Women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES),” Circulation, Vol. 112, 2005, pp. 563-571.
doi:10.1161/CIRCULATIONAHA.104.512681
|
[34]
|
A. Schmermund, S. Achenbach, T. Budde, et al., “Effect of Intensive versus Standard Lipid-Lowering Treatment with Atorvastatin on the Progression of Calcified Coronary Atherosclerosis over 12 Months: A Multicenter, Randomized, Double-Blind Trial,” Circulation, Vol. 113, 2006, pp. 427-437.
doi:10.1161/CIRCULATIONAHA.105.568147
|
[35]
|
R. Saremi, P. D. Reaven and G. Bahn, “For the VADT Investigators. Progression of Vascular Calcification Is Increased with Statin Use in the Veterans Affairs Diabetes Trial (VADT),” Diabetes Care, Vol. 35, No. 11, 2012, pp. 2390-2392. doi:10.2337/dc12-0464
|
[36]
|
J. W. McEvoy, M. J. Blaha, A. P. Defilippis, et al., “Coronary Artery Calcium Progression: An Important Clinical Measurement? A Review of Published Reports,” Journal of the American College of Cardiology, Vol. 56, No. 20, 2010, pp. 1613-1622. doi:10.1016/j.jacc.2010.06.038
|
[37]
|
J. G. Terry, J. J. Carr, E. O. Kouba, et al., “Effect of Simvastatin (80 mg) on Coronary and Abdominal Aortic Arterial Calcium (From the Coronary Artery Calcification Treatment with Zocor [CATZ] Study),” American Journal of Cardiology, Vol. 99, No. 12, 2007, pp. 1714-1717.
doi:10.1016/j.amjcard.2007.01.060
|
[38]
|
D. Lee and A. Goldberg, “Atrogin1/MAFbx: What Atrophy, Hypertrophy, and Cardiac Failure Have in Common,” Circulation Research, Vol. 109, No. 2, 2011, pp. 123-126.
|
[39]
|
P. J. Barter, M. Caulfield, M. Eriksson, S. M. Grundy, J. J. P. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J. C. Tardif, D. D. Waters, C. L. Shear, J. H. Revkin, K. A. Buhr, M. R. Fisher, A. R. Tall and B. Brewer, “For the Illuminate Investigators. Effects of Torcetrapib in Patients at High Risk for Coronary Events,” The New England Journal of Medicine, Vol. 357, 2007, No. 21, pp. 2109-2122.
|